[{"address1": "200 Crossing Boulevard", "city": "Framingham", "state": "MA", "zip": "01702", "country": "United States", "phone": "857 999 0075", "fax": "866 553 3269", "website": "https://www.kalvista.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.", "fullTimeEmployees": 270, "companyOfficers": [{"maxAge": 1, "name": "Mr. Benjamin L. Palleiko", "age": 59, "title": "CEO & Director", "yearBorn": 1966, "fiscalYear": 2025, "totalPay": 1363839, "exercisedValue": 0, "unexercisedValue": 1611947}, {"maxAge": 1, "name": "Mr. Brian  Piekos", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1975, "fiscalYear": 2025, "totalPay": 638486, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Paul K. Audhya M.B.A., M.D.", "age": 53, "title": "Chief Medical Officer", "yearBorn": 1972, "fiscalYear": 2025, "totalPay": 850894, "exercisedValue": 0, "unexercisedValue": 84466}, {"maxAge": 1, "name": "Mr. Bilal  Arif", "age": 53, "title": "Chief Operating Officer", "yearBorn": 1972, "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Baker", "title": "Head of Investor Relations", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian  Krex J.D.", "age": 57, "title": "General Counsel", "yearBorn": 1968, "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Jarrod  Aldom", "title": "Vice President of Corporate Communications", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Linea  Aspesi", "age": 55, "title": "Chief People Officer", "yearBorn": 1970, "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rachel M. Morten", "title": "Senior Vice President of Regulatory Affairs & QA", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christopher M. Yea Ph.D.", "age": 61, "title": "Chief Development Officer", "yearBorn": 1964, "fiscalYear": 2025, "totalPay": 708532, "exercisedValue": 0, "unexercisedValue": 2934521}], "auditRisk": 5, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 5, "overallRisk": 7, "governanceEpochDate": 1769904000, "compensationAsOfEpochDate": 1767139200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 15.89, "open": 15.73, "dayLow": 15.58, "dayHigh": 16.105, "regularMarketPreviousClose": 15.89, "regularMarketOpen": 15.73, "regularMarketDayLow": 15.58, "regularMarketDayHigh": 16.105, "payoutRatio": 0.0, "beta": -0.347, "forwardPE": -10.858977, "volume": 338341, "regularMarketVolume": 338341, "averageVolume": 1197716, "averageVolume10days": 707620, "averageDailyVolume10Day": 707620, "bid": 15.74, "ask": 15.86, "bidSize": 1, "askSize": 1, "marketCap": 800147776, "fiftyTwoWeekLow": 9.235, "fiftyTwoWeekHigh": 19.0, "allTimeHigh": 129.108, "allTimeLow": 4.12, "priceToSalesTrailing12Months": 561.11346, "fiftyDayAverage": 15.6488, "twoHundredDayAverage": 13.59155, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 773568832, "profitMargins": 0.0, "floatShares": 27212102, "sharesOutstanding": 50546293, "sharesShort": 20062100, "sharesShortPriorMonth": 16913184, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.3969, "heldPercentInsiders": 0.01601, "heldPercentInstitutions": 1.3669901, "shortRatio": 15.62, "shortPercentOfFloat": 0.4466, "impliedSharesOutstanding": 50546293, "bookValue": 0.336, "priceToBook": 47.113094, "lastFiscalYearEnd": 1745971200, "nextFiscalYearEnd": 1777507200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -203096992, "trailingEps": -3.94, "forwardEps": -1.45778, "lastSplitFactor": "1:14", "lastSplitDate": 1479772800, "enterpriseToRevenue": 542.475, "enterpriseToEbitda": -3.833, "52WeekChange": 0.5245398, "SandP52WeekChange": 0.11527538, "quoteType": "EQUITY", "currentPrice": 15.83, "targetHighPrice": 39.0, "targetLowPrice": 22.0, "targetMeanPrice": 34.0, "targetMedianPrice": 35.0, "recommendationMean": 1.22222, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 309158016, "totalCashPerShare": 6.116, "ebitda": -201820000, "totalDebt": 282579008, "quickRatio": 5.159, "currentRatio": 5.365, "totalRevenue": 1426000, "debtToEquity": 1662.327, "revenuePerShare": 0.028, "returnOnAssets": -0.60978, "returnOnEquity": -1.90176, "grossProfits": -59421000, "freeCashflow": -100205000, "operatingCashflow": -167188992, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -3.36328, "financialCurrency": "USD", "symbol": "KALV", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1771630953, "regularMarketTime": 1771621202, "marketState": "CLOSED", "shortName": "KalVista Pharmaceuticals, Inc.", "longName": "KalVista Pharmaceuticals, Inc.", "exchange": "NGM", "messageBoardId": "finmb_136678928", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1428586200000, "postMarketChangePercent": 0.12634528, "postMarketPrice": 15.85, "postMarketChange": 0.020000458, "regularMarketChange": -0.0600004, "regularMarketDayRange": "15.58 - 16.105", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 1197716, "fiftyTwoWeekLowChange": 6.5950003, "fiftyTwoWeekLowChangePercent": 0.71413106, "fiftyTwoWeekRange": "9.235 - 19.0", "fiftyTwoWeekHighChange": -3.17, "fiftyTwoWeekHighChangePercent": -0.1668421, "fiftyTwoWeekChangePercent": 52.453983, "dividendDate": 1479772800, "earningsTimestampStart": 1774359000, "earningsTimestampEnd": 1774359000, "earningsCallTimestampStart": 1762867800, "earningsCallTimestampEnd": 1762867800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.94, "epsForward": -1.45778, "epsCurrentYear": -2.78125, "priceEpsCurrentYear": -5.691685, "fiftyDayAverageChange": 0.18120003, "fiftyDayAverageChangePercent": 0.011579164, "twoHundredDayAverageChange": 2.23845, "twoHundredDayAverageChangePercent": 0.16469425, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "regularMarketChangePercent": -0.377599, "regularMarketPrice": 15.83, "displayName": "KalVista Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2026-02-21"}]